Calabrese, V., Giuffrida Stella, A
Tessiatore P, Guana R, Mussa A, Lonati L, Sberveglieri M, Ferrero L, et al
IGF1-LR3, a modified version of insulin-like growth factor-1, has a longer half-life than standard IGF-1 because it does not bind to IGF-1 binding proteins well
Reduces the likelihood of outbreaks
To these is now added a new class of oral drugs, tyrosine kinase two inhibitors, such as Deucravacitinib, approved by regulatory authorities to offer potent systemic efficacy with the convenience of oral administration, representing a valid alternative for patients who prefer to avoid injections